The Hemostatic System in Patients With Type 2 Diabetes With and Without Cardiovascular Disease

被引：23
|
作者：
Verkleij, Chantal J. N. [1 ]
de Bruijn, Roderick E. [2 ]
Meesters, Eelco W. [2 ]
Gerdes, Victor E. A. [2 ,3 ]
Meijers, Joost C. M. [1 ,3 ]
Marx, Pauline F. [1 ]
机构：
[1] Univ Amsterdam, Acad Med Ctr, Dept Expt Vasc Med, NL-1100 DD Amsterdam, Netherlands
[2] Slotervaart Hosp, Dept Internal Med, Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1100 DD Amsterdam, Netherlands
来源：
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS | 2011年 / 17卷 / 06期
关键词：
cardiovascular disease; coagulation; fibrinolysis; hemostasis; type 2 diabetes mellitus; PLASMINOGEN-ACTIVATOR INHIBITOR; VON-WILLEBRAND-FACTOR; 1ST-DEGREE RELATIVES; INSULIN; PLASMA; NIDDM; COMPLICATIONS; COAGULATION; FIBRINOGEN; RISK;
D O I：
10.1177/1076029610384112
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The contribution of the hemostatic system in the development of cardiovascular disease (CVD) in patients with type 2 diabetes is not completely defined. The aim of this study was to elucidate associations of hemostatic factors with the development of CVD in patients with type 2 diabetes. Patients with type 2 diabetes without CVD (n = 113), with CVD (n = 94), and controls without CVD (n = 100) were enrolled in this study. Several hemostatic markers were measured. A disturbed hemostatic balance in patients with type 2 diabetes was observed as illustrated by hypofibrinolysis and increased levels of von Willebrand factor (vWF) and plasminogen-activator inhibitor 1 (PAI-1). Patients with type 2 diabetes with CVD have more thrombin generation compared to patients without CVD. This hemostatic imbalance might contribute to the development of CVD in patients with type 2 diabetes.
引用
收藏
页码：E57 / E63
页数：7
相关论文
共 50 条
  • [31] Antiplatelet effect of aspirin during 24 hours in patients with type 2 diabetes without cardiovascular disease
    Vernstroem, L.
    Funck, K. L.
    Laugesen, E.
    Grove, E. L.
    Hvas, A. -M.
    Poulsen, P. L.
    [J]. DIABETOLOGIA, 2017, 60 : S521 - S521
  • [32] Prescribing in Type 2 Diabetes Patients With and Without Cardiovascular Disease History: A Descriptive Analysis in the UK CPRD
    Farmer, Ruth E.
    Beard, Ivan
    Raza, Syed, I
    Gollop, Nicholas D.
    Patel, Niraj
    Tebboth, Abigail
    McGovern, Andrew P.
    Kanumilli, Naresh
    Ternouth, Andrew
    [J]. CLINICAL THERAPEUTICS, 2021, 43 (02) : 320 - 335
  • [33] Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease
    Fitchett, David
    Inzucchi, Silvio E.
    Lachin, John M.
    Wanner, Christoph
    van de Borne, Philippe
    Mattheus, Michaela
    Johansen, Odd Erik
    Woerle, Hans J.
    Broedl, Uli C.
    George, Jyothis T.
    Zinman, Bernard
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (03) : 364 - 367
  • [34] Prevalence of Heart Failure in Type 2 Diabetes without Prior Cardiovascular Disease
    Tan, K. L.
    Mon, M. O.
    Balkani, D. K. Z.
    AbuBakar, A.
    Baharudin, N. A.
    Ibrahim, L.
    Paramasivam, S. S.
    Ratnasingam, R. J.
    Vethakkan, S.
    Tan, A. T. B.
    Chee, K. H.
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2019, 297 : 12 - 12
  • [35] Cardiovascular disease in type 2 diabetes
    Bloomgarden, ZT
    [J]. DIABETES CARE, 1999, 22 (10) : 1739 - 1744
  • [36] Type 2 diabetes is cardiovascular disease
    Dhatariya, K
    [J]. JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 2003, 96 (08) : 371 - 372
  • [37] Type 2 diabetes and cardiovascular disease
    Einhorn, D
    Rosenstock, J
    [J]. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2005, 34 (01) : XI - XII
  • [38] Value of Estimated Glomerular Filtration Rate and Albuminuria in Predicting Cardiovascular Risk in Patients with Type 2 Diabetes without Cardiovascular Disease
    Weerarathna, Thilak
    Liyanage, Gayani
    Herath, Meththananda
    Weerarathna, Miyuru
    Amarasinghe, Isuru
    [J]. BIOMED RESEARCH INTERNATIONAL, 2018, 2018
  • [39] Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease
    Lim, Jayoung
    Hwang, In-Chang
    Choi, Hong-Mi
    Yoon, Yeonyee E.
    Cho, Goo-Yeong
    [J]. PLOS ONE, 2022, 17 (10):
  • [40] Cardiovascular autonomic neuropathy in patients with type 2 diabetes with and without sensorimotor polyneuropathy
    Peters, Emil
    Itani, Mustapha
    Kristensen, Alexander G.
    Terkelsen, Astrid Juhl
    Kroigard, Thomas
    Tankisi, Hatice
    Jensen, Troels S.
    Finnerup, Nanna B.
    Gylfadottir, Sandra Sif
    [J]. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2023, 28 (03) : 450 - 459
12345